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ABSTRACT
MicroRNAs (miRNA) play pivotal roles in controlling cell proliferation and differentiation. Aberrant miRNA expression in
human is becoming recognized as a new molecular mechanism of carcinogenesis. However, the causes for alterations in miRNA
expression remain largely unknown. Infection with oncogenic human papillomavirus types 16 (HPV16) and 18 (HPV18) can
lead to cervical and other ano-genital cancers. Here, we have demonstrated that cervical cancer tissues and cervical cancer-
derived cell lines containing oncogenic HPVs display reduced expression of tumor-suppressive miR-34a. The reduction of miR-
34a expression in organotypic tissues derived from HPV-containing primary human keratinocytes correlates with the early
productive phase and is attributed to the expression of viral E6, which destabilizes the tumor suppressor p53, a known miR-34a
transactivator. Knockdown of viral E6 expression in HPV16+ and HPV18+ cervical cancer cell lines by siRNAs leads to an
increased expression of p53 and miR-34a and accumulation of miR-34a in G0/G1 phase cells. Ectopic expression of miR-34a in
HPV18+ HeLa cells and HPV HCT116 cells results in a substantial induction of cell growth retardation and a moderate cell
apoptosis. Together, this is the first time a viral oncoprotein has been shown to regulate cellular miRNA expression. Our data
have provided new insights into mechanisms by which high-risk HPVs contribute to the development of cervical cancer.
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INTRODUCTION
Human papillomavirus type 16 (HPV16) or 18 (HPV18)
infection is widely recognized as a leading cause of cervical,
penile, and anal cancers. Two viral oncoproteins, E6 and
E7, of HPV16 and HPV18 are responsible for viral
oncogenesis by destabilizing two major cellular tumor sup-
pressors, p53 and pRb, respectively (Scheffner et al. 1990;
Gonzalez et al. 2001). Tumor suppressor protein p53
functions as a transcription factor in regulating the tran-
scription of many hundreds of protein-coding genes to
safeguard the integrity of the genome by inducing cell cycle
arrest and DNA repair upon encountering DNA damage, or
apoptosis if repair cannot be achieved (Mirza et al. 2003;
Vousden and Lane 2007; Halazonetis et al. 2008). The
hypophosphorylated form of pRb binds to E2F family
transcription factors and controls the G1-to-S transition
of the cell cycle (Chellappan et al. 1992; Cobrinik 2005).
Thus, destabilization of p53 and hypophosphorylated pRb
by the two viral oncoproteins promotes excessive cell
cycling and accumulation of mutations, leading to genome
instability.
MiRNAs represent a new class of noncoding regulatory
RNAs which are 21–25 nucleotides (nt) in length and
modulate gene expression at the post-transcriptional level
by base-pairing with complementary nucleotide sequences
(seed matching) in the 59 and 39 untranslated regions
(UTRs) of target mRNAs (Grimson et al. 2007; Lytle et al.
2007; Nielsen et al. 2007). Approximately 416 miRNA genes
have now been identified in the human genome encoding
z340 distinct mature miRNAs, many of which are tissue-
specific or temporally regulated in their expression (Landgraf
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et al. 2007). However, their biological functions and
molecular targets remain largely undefined and experimen-
tally untested. Deletions or mutations in miRNA genes, as
well as aberrant expression of oncogenic or tumor-sup-
pressive miRNAs, are common in human cancers (Calin
and Croce 2006; Wang et al. 2008), but the causes for their
aberrant expression are poorly understood. Although many
human viruses produce their own viral miRNAs in the
course of virus infection (Pfeffer et al. 2004, 2005; Cai et al.
2005; Samols et al. 2005; Tang et al. 2008; Umbach et al.
2008), there is no report on viral proteins in regulation of
cellular miRNA expression.
Recently, miR-34a was identified as a direct transcrip-
tional target of cellular transcription factor p53 (Chang
et al. 2007; He et al. 2007; Raver-Shapira et al. 2007). This
transactivation of miR-34a expression is triggered by the
binding of p53 to a consensus p53 binding site identified in
the miR-34a promoter region. Since HPV E6 oncoprotein
destabilizes p53 during virus infection, one may assume a
down-regulation of miR-34a expression in most cervical
cancer tissues with oncogenic HPV infection. However, a
direct correlation between down-regulation of miR-34a
expression and p53 degradation by HPV oncoprotein E6
in cervical cancer has not been reported. In this study, we
provide direct evidence that papillomaviral oncoprotein E6
expressed from HPV16 and HPV18 inhibits the expression
of tumor-suppressive miR-34a by destabilization of p53,
resulting in cell proliferation.
RESULTS
Reduction of miR-34a expression in cervical cancer
and cervical cancer-derived cell lines
Our recent study demonstrated that cervical cancer ex-
hibits aberrant expression of several oncogenic and tumor-
suppressive miRNAs (Wang et al. 2008). To investigate
whether oncogenic HPV infection could alter the expres-
sion of certain members of the miRNA family, we exam-
ined three pairs of age-matched normal cervix and cervical
cancer tissues for the expression of tumor-suppressive miR-
34a by Northern blotting. A profound reduction of miR-
34a, which appeared as three separate bands differing by 1
nt and in the sizes of 22–24 nt, was detected in all three
cervical cancer tissues, each with a high-risk HPV infection
(Fig. 1A,B; Munoz et al. 2003). The heterogeneity of miR-
34a in normal cervix and cervical cancer tissues was
probably due to wobble digestion of the pre-miRNA by
dicer as recently reported (Landgraf et al. 2007; Wang et al.
2008). The observed reduction of miR-34a in cervical
cancer was further confirmed by another method, miRNA
ligation assay (Maroney et al. 2007) from a pair of
commercially obtained RNA samples derived from normal
cervix and cervical cancer tissues (Fig. 1C, lanes 2,3).
Consistent with this finding, a remarkable reduction of
miR-34a was found in all cervical cancer-derived cell lines
containing integrated oncogenic HPV DNA (Fig. 1C, lanes
4–8) and an HPV-negative human keratinocyte line HaCaT
(Fig. 1C, lane 10). There was no miR-34a production in an
HPV-negative cervical cancer cell line C33A (Fig. 1C, lane
9). Both HaCaT and C33A cells contain a mutant p53
(Crook et al. 1991; Lehman et al. 1993).
High-risk HPV infection reduces miR-34a expression
in host cells
To determine whether HPV infection causes a reduction of
miR-34a prior to cancer development, human primary
keratinocytes HVK from adult vaginal tissues or HFK from
newborn foreskins were immortalized with oncogenic
HPV16 or HPV18 genomic DNA and then grown as
organotypic raft cultures on dermal equivalents consisting
FIGURE 1. Reduction of miR-34a in cervical cancer tissues and
cervical cancer-derived cell lines. (A) Cervical cancer tissues express a
reduced level of miR-34a. Three age-matched pairs of normal cervix
and cervical cancer tissues, each positive for a single genotype
(HPV16, 82, or 33), were compared for miR-34a expression by
Northern blotting. (B) Bar graph showing relative levels of miR-34a
in A after being normalized to U6 snRNA for sample loading. (C) A
substantial reduction of miR-34a occurs in cervical cancer-derived cell
lines or in human keratinocyte line HaCaT cells with a mutant p53.
(Top panel) Total RNAs from individual cell lines were examined by
miRNA ligation analyses. Paired total RNAs from normal cervix (N
Cx), cervical cancer (CxCa) obtained from Ambion and a miRNA-
positive (Pos.) control from USB were used as controls for this
analysis. (D) Bar graph showing relative levels of miR-34a in each
sample in C after being normalized to tRNA (bottom in C) for sample
loading.
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of collagen with embedded fibroblasts. Total RNA isolated
from the raft cultures derived from control keratinocytes or
HPV-immortalized keratinocytes was examined by North-
ern blot hybridization. A prominent reduction of miR-34a
expression was observed in the raft cultures of the cells
immortalized with HPV16 or HPV18 (Fig. 2). HVK, which
produces much more miR-34a than HFK, appeared to be
more sensitive than HFK for the reduction of miR-34a by
high-risk HPV16 and HPV18 infection (Fig. 2A,B). Since
cell immortalization by high-risk HPVs is a function of
viral oncoproteins E6 and E7 (Munger et al. 2004), these
data suggest a possible role of viral oncoproteins in the
reduction of miR-34a expression.
We next examined the expression of miR-34a in the raft
cultures prepared from HFKs containing HPV18 genomic
plasmids without prior immortalization. In this approach,
HFK from newborn foreskins was transfected with HPV18
genomic plasmids using Cre-mediated recombination and
then put on raft culture for sample collection at days 8, 12,
and 16. As shown in Figure 3A, HPV18-infected HFK raft
cultures, when compared to noninfected ones, grew much
faster with a thicker keratinocyte layer at all time points due
to HPV18 infection-increased HFK proliferation and led to
production of infectious viruses at day 12 and day 16 as
indicated by the expression of the major viral capsid protein
L1. Relative to control cultures, a notable reduction of miR-
34a in 8-d-old HPV18-containing raft cultures prior to L1
expression could be observed despite RNA overloading as
assessed by its U6 level (Fig. 3B, lane 4). After quantification
and normalization to U6 loading, a greater than twofold
reduction of miR-34a levels was obtained in the 8-d-old rafts
with HPV18 infection (Fig. 3C). These results further imply
that viral early proteins are directly involved in the down-
regulation of miR-34a expression.
A functional p53 is important in the expression
of miR-34a in cancer cells, but may be not fully
responsible for miR-34a expression in the late
stage raft cultures with acute HPV18 infection
As the expression of miR-34a is transactivated by p53
binding to a perfect p53 binding site in the miR-34a
regulatory region (Chang et al. 2007; He et al. 2007;
Raver-Shapira et al. 2007), we wish to investigate whether
cellular p53 is directly involved in the expression of miR-
34a in cervical cancer and cervical cancer-derived cell lines.
The HPV-negative cervical cancer cell line, C33A, was
chosen for the study because C33A is expressing a mutant
form of p53 (Scheffner et al. 1991) and consequently no
detectable miR-34a in a miRNA ligation assay (Fig. 1C),
which is in contrast to HaCaT cells, an HPV-negative
keratinocyte line. Although also expressing a mutant form
of p53 (Lehman et al. 1993), the HaCaT cells do express
miR-34a at a substantially reduced level (Fig. 1C). As
shown in Figure 4A, both C33A and HPV16+ CaSki express
a similar amount of miR-16 in Northern blot analyses, but
C33A expresses no detectable miR-34a by Northern blot-
ting (Fig. 4A, left panel). However, when wild-type p53 was
ectopically expressed for 24 h in C33A cells by transient
transfection, a substantial induction of miR-34a expression
became prominent (Fig. 4A, right panel), indicating that
the reduced indeed is related directly to destabilized or
dysfunctional p53 in cervical cancer cells.
Although miR-34a expression can be transactivated by
p53 in cervical cancer cells, an increased expression of miR-
34a was found not fully associated with cellular p53 level in
the late stage of HFK raft cultures with HPV18 infection. As
shown in Figure 4B, a decreased expression of miR-34a was
associated with a decreased level of p53 in the early stage
(day 8) of HFK raft cultures with HPV18 infection.
However, relative to the control raft cultures, miR-34a
expression was restored in day 12 and day 16 HPV18 raft
cultures (Fig. 4B) on or after capsid protein synthesis (Fig.
3A), when there was a high level of viral E7-mediated
p21cip1 and a further reduced expression of p53, implying
FIGURE 2. Reduction of miR-34a expression in oncogenic HPV-
immortalized keratinocytes. (A) Down-regulation of miR-34a in raft
cultures derived from HVK or HFK immortalized in vitro by HPV16
or HPV18. Total RNA from each raft culture harvested on day 10 was
examined by Northern blotting. (B) Bar graph showing relative miR-
34a levels in A after being normalized to U6 snRNA for sample
loading.
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the presence of a p53-independent pathway in the expres-
sion of miR-34a in this system.
Expression of high-risk HPV oncoprotein E6 reduces
miR-34a expression by destabilizing p53
Since HPV E6 and E7 are two major viral early proteins
produced in the early phase of viral infection and are
expressed at elevated levels in cervical cancer and their
derived cell lines (Munger et al. 2004; Tang et al. 2006b),
we next investigated viral E6 expression in correlation with
p53 and miR-34a production in HPV18+ HeLa cells and
HPV16+ CaSki cells that express the wild-type p53.
Through this study, we wish to provide a direct connection
of viral E6 oncoprotein to p53 and miR-34a circuit in
HPV infection. As shown in Figure 5, knocking down the
expression of HPV18 E6 by an HPV18 E6-specific siRNA
(Tang et al. 2006b) in HeLa cells stabilized p53 and induced
the expression of p21cip1, a downstream target of p53
transcriptional activation (Fig. 5A,B). As expected, stabili-
zation of p53 in HeLa cells by knocking down HPV18 E6
highly up-regulated miR-34a expression (Fig. 5C,D). Con-
sistent with this observation, knocking down the expression
of HPV16 E6 in CaSki cells by an HPV16 E6-specific siRNA
also stabilized p53 (Tang et al. 2006b) and up-regulated the
expression of miR-34a (Fig. 5E–G).
These observations were further verified in HFKs acutely
transduced with HPV18 E6, E7, E6E7, or an empty control
FIGURE 3. HPV early proteins down-regulate the expression of miR-
34a in HPV18-infected raft cultures. (A) Kinetics of the production of
HPV18 L1 in HFK raft cultures. L1 was detected by immunohisto-
chemistry (reddish brown) in terminally differentiated keratinocytes
and cornified envelopes at 12-d-old and 16-d-old HPV18-containing
HFK raft cultures. (B) Reduction of miR-34a expression in raft
cultures of HPV18 DNA-containing HFKs (HFK18) without immor-
talization on day 8, but not on days 12 and 16. Total RNAs from raft
cultures of different ages were examined by Northern blotting. (C) Bar
graph showing relative miR-34a levels in B after being normalized to
U6 for sample loading. FIGURE 4. Role of wild-type p53 in activation of miR-34a expression
from C33A cells and HFK raft cultures with HPV18 infection. (A)
Overexpression of wild-type p53 activates miR-34a expression from
C33A, an HPV-negative cervical cancer cell line containing a mutant
(mt) form of p53. (Left panel) Shows no detectable expression of miR-
34a, but miR-16 in C33A cells in comparison with CaSki (HPV16+)
cells containing a wild-type (wt) p53 with detectable expression of
both miR-34a and miR-16 by Northern blot analyses. (Right panel)
Shows miR-34a expression in C33A cells transactivated by ectopic
expression of wild-type p53 at 24 h after transfection. (B) Destabili-
zation of p53 down-regulates the expression of miR-34a in the early,
but not in the late HFK raft cultures with HPV18 infection. Raft
cultures of HFKs containing HPV18 were harvested on day (D) 8, 12,
and 16 and were analyzed for miR-34a expression by Northern
blotting and for p53 and p21cip1 production by Western blotting.
(A,B) U6 in each sample served as RNA sample loading in Northern
blots. (B) Tubulin in each sample served as protein sample loading in
Western blots.
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retrovirus (Cheng et al. 1995; Banerjee et al. 2005). When
HFKs acutely transduced with HPV18 E6 or E7 retrovirus,
only the expression of E7 in HFK rafts induced S phase
reentry in differentiated keratinocytes (Fig. 6A) and stabili-
zation of p21cip1 (Fig. 6B, top panels), as reported from
previous studies (Park et al. 2000; Noya et al. 2001). As
predicted, a substantial down-regulation of miR-34a expres-
sion was evident only in the E6- or E6E7-expressing raft
cultures, but not in E7-expressing raft cultures, relative to
cultures infected with vector-only retrovirus (Fig. 6B, lower
panels; Fig. 6C). This result correlatedwith E6 destabilization
of p53 (Fig. 6B, top panels), but not with E7-induced
S-phase reentry in differentiated HFKs
(Fig. 6A), nor its stabilization of p21cip1
(Fig. 6B, top panels). Collectively, these
data indicate that the viral oncoprotein
E6 is responsible for the observed down-
regulation of miR-34a expression in
oncogenic HPV-infected cells.
Down-regulation of miR-34a
expression in HPV-infected cells by
viral E6 promotes cell proliferation
To determine whether the E6-mediated
down-regulation of miR-34a expression
is important for the development of
cervical cancer, we first demonstrated
that the majority of miR-34a in HeLa
cells treated with an E6-specific siRNA
(Tang et al. 2006b), which stabilized
p53 and up-regulated miR-34a (Fig.
5A–D), was found in G0/G1-phase cells
upon cell sorting. There was a much
higher miR-34a ratio (5.5-fold) of G0/
G1 versus S/G2/M in E6 siRNA-treated
cells than that in control siRNA-treated
cells (Fig. 7A,B), consistent with p53
nuclear retention and its highest DNA
binding and transactivation activity at
the cell G1/S transition (Fogal et al.
2005). We next examined ectopic ex-
pression of miR-34a on HeLa cell
growth. Because E7 destabilizes hypo-
phosphorylated pRb in cervical cancer
cells, E7-expressing cells lack an efficient
checkpoint control in the G1 phase of
the cell cycle and resist G1 growth arrest
(Slebos et al. 1994; Jones and Munger
1997). Consistent with this, the ectopic
expression of miR-34a in HeLa cells had
no effect on G1 phase, but led to a
moderate cell cycle arrest at the S and
G2/M phases and apoptosis (Fig. 8A,B).
More importantly, there was a substan-
tial growth retardation in HeLa cells with the ectopic
expression of miR-34a (Fig. 8C,D). This suppressive effect
on the cell growth was not an immediate cell response;
rather, it took a few days to become prominent after two
consecutive miR-34a transfections at an interval of 48 h
(Fig. 8C). We infer from these results that cervical cancer
cells with low miR-34a expression levels have a growth
advantage. Moreover, these effects appear to be indepen-
dent of the status of p53 and pRb, as in HPV-negative
HCT116 cells, a cell line derived from colon cancer that
contains wild-type p53 and increased pRb (Yamamoto
et al. 1999) and thus has a functional G1 checkpoint, the
FIGURE 5. Down-regulation of miR-34a by HPV oncoprotein E6 in cervical cancer-derived
cell lines. (A) Strategy to silence E6 oncogene expression using an E6 intron-specific siRNA
based on splicing of the bicistronic HPV18 E6E7 RNAs (Tang et al. 2006b). (B) Stabilization of
p53 and activation of p21cip1 in HPV18 E6 siRNA-treated HeLa cells. Cell samples at 48 h after
siRNA transfection were examined by Western blotting with tubulin as a loading control. (C)
Knocking down E6 expression by an E6-specific siRNA up-regulates the expression of miR-34a
in HeLa cells. Total cell RNA 48 h after an E6-specific siRNA (Tang et al. 2006b) transfection
was examined by miRNA ligation analyses (Maroney et al. 2007). (D) Bar graph showing
relative miR-34a levels detected in C after being normalized to tRNA for sample loading. (E)
Diagram of siRNA targeting to HPV16 E6 (Tang et al. 2006a,b). (F) Knocking down the
expression of HPV16 E6 by an E6-specific siRNA promotes the expression of miR-34a in CaSki
cells by Northern blotting. (G) Bar graph showing relative miR-34a levels after being
normalized to U6 snRNA for sample loading.
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ectopic expression of miR-34a mediated a moderate cell
cycle arrest at G1 and caused cell apoptosis and growth
retardation (data not shown) in a dose-dependent manner.
Similar to HeLa cell growth inhibition, this suppressive
effect on HCT116 cell growth by miR-34a was found not to
be an immediate cell response.
DISCUSSION
Although almost all human cancers examined to date
display a certain level of aberrant miRNA expression or
have mutant forms of miRNA, we know very little about
their role in cancer or the cause leading to the aberrant
expression. So far, there has been no report whether virus
infection could regulate the expression of cellular miRNAs.
In this study, we have demonstrated for the first time that
miR-34a is down-regulated in productive, pre-malignant
HPV infections, cervical cancer tissues, and cervical cancer
cells (Figs. 1–3). This down-regulation can be attributed to
the high-risk HPV E6 oncoprotein (Figs. 5,6), which
mediates degradation of p53, a known regulator of miR-
34a transcription (Chang et al. 2007; He et al. 2007; Raver-
Shapira et al. 2007). This is the first compelling evidence to
show a viral oncoprotein being involved in regulation of
cellular tumor suppressive miRNAs. On the basis of these
observations, we have added a new dimension to HPV-
initiated carcinogenesis (Fig. 9). Viral oncoprotein E6 desta-
bilizes p53 and consequently down-regulates the expression
of tumor-suppressive miR-34a, providing the cells with a
growth advantage. This untimely up-regulation of the viral
oncoprotein E6, together with viral oncoprotein E7, which
degrades pRb, can result in excessive cell proliferation,
initiating the neoplastic and oncogenic processes. As low-
risk HPV E6 does not degrade p53 (Tao et al. 2003), we
presume that the low-risk E6 might have no effect on the
expression of miR-34a.
Although miR-34a expression can be transactivated by
p53 in this study and in several reports (Chang et al. 2007;
He et al. 2007; Raver-Shapira et al. 2007), the expression of
miR-34a might take place in a p53-independent manner
under some particular conditions. The finding that miR-
34a expression was restored in this report in day 12 and day
16 HPV18 raft cultures on or after capsid protein synthesis,
FIGURE 6. Down-regulation of miR-34a expression by HPV18 E6 in
HFK raft cultures. (A) S-phase re-entry by differentiated keratinocytes
in raft cultures of HFKs transduced with HPV18 E6 or E7 retroviruses.
BrdU incorporation was used to show E7-mediated S-phase re-entry.
(B) Destabilization of p53 and reduction of miR-34a expression in raft
cultures of HFKs acutely transduced with E6 or E6E7, but not by E7,
retroviruses. Raft cultures with or without the corresponding retro-
virus infection were harvested on day 10 for detection of p53 and p21
by (upper panel) Western (W) blotting or for total RNA preparation
and (lower panel) Northern blotting. Tubulin served as protein sample
loading in Western blotting. (C) Bar graph showing relative miR-34a
levels detected by Northern blotting in B after being normalized to U6
for sample loading.
FIGURE 7. Accumulation of miR-34a in G0/G1-phase HeLa cells
after transfection of E6-specific siRNA. (A) HeLa cells 48 h following
treatment with or without an HPV18 E6-specific siRNA (Tang et al.
2006b) were sorted into G0/G1 and S/G2/M subpopulations by flow
cytometry, and total RNA from each subpopulation was quantified for
miR-34a expression by miRNA ligation analyses. (B) A ratio of miR-
34a levels in the two subpopulations from each group was calculated
after being normalized to tRNA for sample loading. One representa-
tive experiment of two is shown.
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when there was a further reduced expression of p53 and a
high level of viral E7-mediated p21cip1, clearly suggests the
presence of a p53-independent pathway in the expression
of tumor suppressive miR-34a. We postulate that other
transcription factors or chromatin remodeling in the
differentiated HFKs must be involved in regulation of
miR-34a transcription. A recent study shows that miR-
34a expression can be inactivated by CpG methylation of its
promoter (Lodygin et al. 2008).
The findings of miR-34a substantially
accumulated in the G0/G1 phase and
only a low level in the S/G2/M phase in
E6 siRNA-treated HeLa cells suggest an
elevated expression or stability of miR-
34a in G0/G1-phase cells. This elevated
steady-state miR-34a level in G0/G1-
phase cells would contribute to an
increased cell population arrested at
the G1 phase when a functional G1
checkpoint is present in HPV-negative
HCT116 cells (data not shown) or other
cell lines (He et al. 2007; Tarasov
et al. 2007). As nuclear retention and
transactivation functions of Ser315-
phosphorylated p53 are the highest at
the G1/S transition and the Ser315
phosphorylation by increased cyclin A
expression in the S phase could decrease
p53 nuclear activities by promoting p53
nuclear export (Fogal et al. 2005), the
elevated steady-state miR-34a level in
G0/G1 phase cells observed in this study
could be simply ascribed to this cell
cycle-dependent nuclear retention and
activities of Ser315-phosphorylated p53.
Cell cycle-dependent changes in miRNA
stability have been recently reported in
HeLa cells, in which miR-29a and miR-
30 were found to be constitutively ex-
pressed in all cell cycle phases, but miR-
29b was expressed highly only in
mitotic cells (Hwang et al. 2007). Thus,
our data together with this report indi-
cate a cell cycle-dependent regulation of
miRNA expression and stability in con-
trolling miRNA functions.
MiRNAs exercise large-scale effects on
the expression of a variety of genes at the
post-transcriptional level, and are esti-
mated to regulate z30% of mammalian
genes. By prediction and experimental
analyses, any given miRNA may have
hundreds of gene targets (Brennecke
et al. 2005; Farh et al. 2005; Lewis et al.
2005). In this study, we have demon-
strated that cells with a reduced level of miR-34a expression
have a growth advantage since the ectopic expression ofmiR-
34a induces cell growth retardation and amoderate cell cycle
arrest and apoptosis. As a moderate cell cycle arrest and
apoptosis observed in this study might not fully cause a
substantial cell growth retardation in the cells with the
ectopic expression of miR-34a, the growth retardation
mediated by miR-34a could be ascribed to many other
unnoticed effects of miR-34a. For example, miR-34a has
FIGURE 8. Expression of miR-34a in HPV18+ HeLa cells leads to growth retardation, cell
cycle arrest, and apoptosis. (A,B) ectopic expression of miR-34a in HeLa cells leads to (A) cell
cycle arrest at G2 and (B) apoptosis. Flow cytometry was conducted with cells transfected twice
with miR-34a at an interval of 48 h. (Arrows) Indicate the cell numbers at G2. (C,D) Ectopic
expression of miR-34a in HeLa cells suppresses cell growth. (C) HeLa cells received miR-34a
transfections (arrows mark transfection time points), and total viable cells were counted. (D)
Total cell RNA after miR-34 transfection was analyzed by miRNA ligation analyses and tRNA
served as a loading control.
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been found to target multiple cell cycle components, includ-
ing CDK4, cyclin E2, E2F-1, hepatocyte growth factor
receptor MET, and Bcl-2 in other studies (Bommer et al.
2007; He et al. 2007; Tazawa et al. 2007; Welch et al. 2007).
This multitargeting capacity by a single miRNA on cell
cycling machinery may fine-tune a checkpoint for cell cycle
progression. Recently, we also found that the ectopic expres-
sion of certain tumor-suppressive or oncogenic miRNAs
affects cell doubling time (Wang et al. 2008). Thus, an
efficient cell growth retardation mediated by miR-34a could
result from a collection ofmanymiR-34a–target interactions
in spite of the fact that the exact mechanism by which miR-
34a might function remains to be understood.
In summary, this is the first time that a viral oncoprotein
has been shown to regulate cellular noncoding gene expres-
sion and the first report of viral regulation of expression of a
tumor suppressor miRNA. We have shown that at all stages
of pathogenesis induced by the high-risk HPV types, the E6
destabilization of the tumor suppressor p53 down-regulates
the tumor-suppressive miR-34a, leading to the elevated
expression of cell cycle regulators and cell proliferation.
These intimate interplays among viral E6, p53, miR-34a, and
E7 place miR-34a in a central role in a well-known viral
oncoprotein–tumor suppressor network.
MATERIALS AND METHODS
Cell lines and human tissues
HPV16-positive cell lines CaSki and SiHa, HPV18-positive cell
lines HeLa and C411, HPV68-positive cell line ME180 (Longuet
et al. 1996), HPV-negative cervical cancer cell line C33A, and
HPV-negative human keratinocyte line HaCaT cells (Stanley et al.
1989) were used in this study. All of these cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM) with 10% FBS at
37°C and 5% CO2. HCT116 cells derived from colon cancer were
grown in McCoy’s 5A medium with 10% FBS. Normal cervix and
cervical cancer tissues were obtained from women with an age
range from 40 to 50 yr old. HPV genotyping was done by
sequencing-based techniques as previously described (Zhang
et al. 2007). Use of these tissues was approved both by the
Washington University Medical Center Human Studies Committee
and by the NIH Office of Human Subjects Research. Each tissue
was homogenized in an Eppendorf tube in 1 mL of TRIzol Reagent
(Invitrogen) using an electric homogenizer (Omni International)
with a separate disposable probe. The isolated RNA was dissolved
in RNase-free water and stored at 70°C.
Northern blot analysis
Total RNA (30–40 mg) was separated on a 15% denaturing
polyacrylamide gel and transferred onto a GeneScreen Plus
Hybridization Transfer Membrane (PerkinElmer) in 0.53 TBE
buffer. The membrane was pre-hybridized with PerfectHyb Plus
hybridization buffer (Sigma) for 2 h and then hybridized with
[g-32P]-labeled miRNA-specific antisense probe overnight at
40°C. The membrane was washed sequentially in 50 mL of 23
SSPE containing 0.5% SDS, 0.53 SSPE containing 0.5% SDS, and
0.23 SSPE containing 0.1% SDS for 30 min each at 40°C, and
then exposed to a PhosphorImager screen. The image was
captured using a Molecular Dynamics PhosphorImager Storm
860 and analyzed with ImageQuant software. The same membrane
was stripped with 0.13 SSPE, 0.5% SDS for 20–30 min at 90°C
and equilibrated with hybridization buffer for 2 h and then
hybridized with the U6 snRNA probe. The antisense oligodeox-
ynucleotide probes were designed based on individual miRNA
sequences deposited in miRBase (http://microrna.sanger.ac.uk).
An antisense oligodeoxynucleotide (oST197, 59-AAAATATGGA
ACGCTTCACGA-39) was used to detect U6 snRNA from each
sample as a loading control.
miRNA ligation assay
The miRNA ligation assay (Maroney et al. 2007) was performed
using the miRtect-IT miRNA Labeling and Detection Kit (USB).
In brief, detection oligo (oXHW66, 59-CGCTTATGACATTC-39)
was 59-end-labeled with [g-32P]ATP and OptiKinase. The miRNA
in total RNA and the radiolabeled detection oligodeoxynucleotide
were captured with miR-34a-specific bridge oligodeoxynucleotide
(oXHW 79, 59-GAATGTCATAAGCG/ACAACCAGCTAAGACA
CTGCCA-39), and these were then ligated with T4 DNA ligase.
The ligated miRNA was separated on a 15% denaturing poly-
acrylamide gel and exposed to a PhosphorImager screen for 2.5 h.
The image was captured and analyzed as described above. After
exposure, the gel was stained for tRNAs from each sample as a
loading control with ethidium bromide (Yi et al. 2006). Depend-
ing on the designed bridge oligonucleotide, the miRNA ligation
assay detects only one isoform of the interested miRNA.
Western blot analysis
Twenty-five microliters of cell protein lysates were denatured by
boiling for 5 min and separated in a NuPAGE 4%–12% Bis-Tris gel
(Invitrogen) in 13NuPAGEMES SDS running buffer (Invitrogen).
After transfer, the nitrocellulose membrane was blocked with 5%
nonfat drymilk in Tris-buffered saline (TBS) (10mMTris, 150mM
NaCl at pH 7.4) for 1 h at room temperature. After a brief wash with
FIGURE 9. A model for miR-34a expression and its role in the
development of cervical cancer. (Left) Normal cells express wt p53,
which activates the expression of tumor-suppressive miR-34a to
control cell proliferation and growth. Viral E6 expression from
oncogenic HPVs causes the destabilization of cellular p53 and
reduction of tumor-suppressive miR-34a, leading to uncontrolled cell
proliferation and development of cancer. (Black box) p53 binding site;
(shaded box) miR-34a coding region.
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TBS, the membrane was incubated overnight at 4°C with primary
antibody. The membrane was washed three times with TTBS (TBS
with Tween 20 at a final concentration of 0.05% [vol/vol]).
Horseradish peroxidase-labeled secondary antibody (Sigma) di-
luted 10,000-fold in TTBS was incubated for 1 h at room tem-
perature. After thorough washing, the immunoreactive proteins
were detected with enhanced chemiluminescence using SuperSignal
West Pico Western chemiluminescence substrate (Pierce). The
signal was captured on X-ray film. The membrane was stripped
and reprobed with another primary antibody. The primary mono-
clonal antibodies used were anti-p53 (Calbiochem; Ab-6, 1:100),
anti-p21cip1 (BD Pharmingen; 6B6, 1:100), and anti-b-tubulin
antibody (BD Pharmingen, 5H1, 1:1000).
Cell transfection
HeLa cells and HCT116 cells were transfected with 15 or 30 nM
miR-34a Pre-miR Precursor (Ambion) or negative nonspecific
control Pre-miR Precursor (Ambion) using siPORT NeoFX
Transfection Agent (Ambion, Cat #4511) according to the
manufacturer’s instructions. After 48 h, the cells were counted
and transfected again with each corresponding miRNA with the
same dose. After an additional 48 h, the cells were counted, and
total RNA was extracted with TRIzol Reagent.
HPV-negative cervical cancer cells C33A at 5 3 105/mL in a 6-
well plate were transfected with 4 mg/well of a wild-type p53
expression vector or an empty control vector using Lipofectamine
2000. Total RNA was prepared for Northern blotting 24 h after
transfection.
RNAi interference
Ten, 50, or 100 nM synthetic double-stranded siRNA 219, which
targets the HPV18 E6 coding region in intron 1 (nucleotides 353
to 371), or 40 nM synthetic double-stranded siRNA 209, which
targets the HPV16 E6 coding region in intron 1 (nucleotides 277
to 298) (Tang et al. 2006b), were transfected into HeLa cells or
CaSki cells, respectively, with siPORT NeoFX Transfection Agent
(Ambion). Cells were seeded in triplicate in 6-well plates. Forty-
eight hours post-transfection, total cell protein lysates were pre-
pared by the addition of 23 sodium dodecyl sulfate (SDS) loading
buffer, and total RNA was extracted with TRIzol Reagent
(Invitrogen).
Flow cytometry
Apoptosis in HeLa or HCT116 cells was analyzed using Annexin
V-FITC Apoptosis Detection Kit II (BD Pharmingen). Cells were
trypsinized, washed twice with cold PBS, and then resuspended in
13 binding buffer at 13 106 cells/mL. Five microliters of annexin
V-FITC and 5mL of propidium iodide (PI) were added to 100mL of
cells (13 105 cells) in a 5-mL culture tube and incubated for 15min
at room temperature in the dark. After incubation, 400 mL of 13
binding buffer was added to each tube, and the samples were
analyzed by flow cytometry within 1 h. For cell cycle analysis, the
cells in suspension were stained with propidium iodide and
analyzed by flow cytometry. For cell sorting and miR detection,
HeLa cells at 2.33 105/mL were transfected with 10 nM siRNA 219
(HPV18 E6 siRNA) (Tang et al. 2006b) with siPORT NeoFX
Transfection Agent (Ambion). After 48 h of incubation, cells were
trypsinized, resuspended in serum-freemedium at 33 106 cells/mL,
and stained with 15 mg/mL Hoechst 33342 (Invitrogen) for 1.5 h at
37°C. After pelleting by a brief centrifugation, the cells were
resuspended in 500 mL of serum-free medium and subjected to cell
sorting by flow cytometry. Total RNA from the sorted cells was
extracted with TRIzol Reagent for miRNA detection.
Primary human keratinocytes, retrovirus infection,
and organotypic cultures
Primary human foreskin keratinocytes (HFKs) and human vaginal
keratinocytes (HVKs) were cultured in KSFM (Invitrogen) as
described previously (Dollard et al. 1992; Meyers et al. 1992) and
immortalized by HPV16 or HPV18 genomic DNA. Raft cultures
were prepared as described (McLaughlin-Drubin and Meyers
2005). The method to generate HPV18 genomic plasmids using
Cre-mediated recombination in transfected HFKs, without im-
mortalization as well as the production of infectious HPV18 prog-
eny viruses in raft cultures, has been described elsewhere (Wang
et al. 2009).
The empty retroviral vector pLC and the pLJ HPV18 URR E6/
E7 have been described previously (Cheng et al. 1995). The viral
oncogenes are under the control of the homologous 1-kb
contiguous upstream regulatory region (URR) containing tran-
scription enhancers and the E6 promoter. The pLC-18URR-LLE7
has a URR in control of the expression of the HPV18 E7 gene with
a long 59 UTR derived from a truncated E6 gene (Genovese et al.
2008). The pLJ-18URR-E6 was derived from pLJ-18URR-E6E7 by
removing the HPV18 sequences downstream from E6 between
flanking Nsi1 sites. Amphotropic recombinant retroviruses were
prepared from GP+envAM12 (ATCC). Infected HFKs were
selected with 250 mg/mL G418 for 2 d and then develop into
organotypic cultures as previously described (Wilson et al. 1992;
Cheng et al. 1995; Banerjee et al. 2005). The medium was
supplemented with 50 mg/mL BrdU for 12 h immediately before
harvest on day 10 to mark cells in S phase. The raft cultures were
collected free from collagen (no fibroblasts) at specified time
points and frozen in dry ice for total RNA and/or protein
preparation or were formalin-fixed and paraffin-embedded for
in situ analysis.
Immunohistochemistry and microscopy
Four-micrometer sections of raft culture were deparaffinized and
stained with hematoxylin and eosin or subjected to immunohis-
tochemistry. BrdU was detected with the mouse anti-BrdU
antibody (1:100 dilution; Calbiochem) followed by Alexa 555-
conjugated goat anti-mouse antibody (1:200 dilution; Invitrogen/
Molecular Probes). Images were acquired with an Olympus AX70
fluorescence microscope with Speicher filters (Chroma) and a Carl
Zeiss Axiocam HR digital camera. The HPV18 L1 major capsid
protein was detected with a monoclonal primary antibody K1H8
(1:100; DakoCytomation Inc.) and reacted with Concentrated
Detection System (BioGenex) and DAB kit (Innovex Biosciences).
The sections were counterstained with hematoxylin and mounted
with Permount. Images were captured with an Olympus BH2
microscope using a SPOT camera (Diagnostic Instruments).
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